Evidence map›Paper›PMID 39420962›Full record

ArticleBrain communications2024

A novel tauopathy model mimicking molecular and spatial aspects of human tau pathology.

Rin Yanai, Tomoki T Mitani, Etsuo A Susaki, Takeharu Minamihisamatsu, Masafumi Shimojo, Yuri Saito, Hiroshi Mizuma, Nobuhiro Nitta, Daita Kaneda, Yoshio Hashizume and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rin YanaiAdvanced Neuroimaging Center, Institute for Quantum Medical Sciences, National Institutes for Quantum Science and Technology, Chiba, 263-8555, Japan.
Tomoki T MitaniLaboratory for Synthetic Biology, RIKEN BDR, Suita, Osaka, 565-0871, Japan.
Etsuo A SusakiLaboratory for Synthetic Biology, RIKEN BDR, Suita, Osaka, 565-0871, Japan.
Takeharu MinamihisamatsuAdvanced Neuroimaging Center, Institute for Quantum Medical Sciences, National Institutes for Quantum Science and Technology, Chiba, 263-8555, Japan.
Masafumi ShimojoAdvanced Neuroimaging Center, Institute for Quantum Medical Sciences, National Institutes for Quantum Science and Technology, Chiba, 263-8555, Japan.
Yuri SaitoDepartment of Biochemistry and Systems Biomedicine, Graduate School of Medicine, Juntendo University, Tokyo, 113-8421, Japan.
Hiroshi MizumaAdvanced Neuroimaging Center, Institute for Quantum Medical Sciences, National Institutes for Quantum Science and Technology, Chiba, 263-8555, Japan.
Nobuhiro NittaAdvanced Neuroimaging Center, Institute for Quantum Medical Sciences, National Institutes for Quantum Science and Technology, Chiba, 263-8555, Japan.
Daita KanedaDepartment of Neuropathology, Choju Medical Institute, Fukushimura Hospital, Aichi, 441-8124, Japan.
Yoshio HashizumeDepartment of Neuropathology, Choju Medical Institute, Fukushimura Hospital, Aichi, 441-8124, Japan.
Gen MatsumotoDepartment of Neurological Disease Control, Osaka Metropolitan University, School of Medicine, Osaka, 545-8585, Japan.
Kentaro TanemuraLaboratory of Animal Reproduction and Development, Graduate School of Agricultural Science, Tohoku University, Miyagi, 980-8572, Japan.
Ming-Rong ZhangDepartment of Advanced Nuclear Medicine Science, Institute for Quantum Medical Sciences, National Institutes for Quantum Science and Technology, Chiba, 263-8555, Japan.
Makoto HiguchiAdvanced Neuroimaging Center, Institute for Quantum Medical Sciences, National Institutes for Quantum Science and Technology, Chiba, 263-8555, Japan.
Hiroki R UedaLaboratory for Synthetic Biology, RIKEN BDR, Suita, Osaka, 565-0871, Japan.
Naruhiko SaharaAdvanced Neuroimaging Center, Institute for Quantum Medical Sciences, National Institutes for Quantum Science and Technology, Chiba, 263-8555, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Creating a mouse model that recapitulates human tau pathology is essential for developing strategies to intervene in tau-induced neurodegeneration. However, mimicking the pathological features seen in human pathology often involves a trade-off with artificial effects such as unexpected gene insertion and neurotoxicity from the expression system. To overcome these issues, we developed the rTKhomo mouse model by combining a transgenic CaMKII-tTA system with a P301L mutated 1N4R human tau knock-in at the

Indexed as

model mousetauopathytau pathologytissue clearingwhole brain

Identifiers

PMID39420962
PMCPMC11483584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.